BIO Statement on Proposed Part B Drug Payment Model

BIO Statement on Proposed Part B Drug Payment Model

MARCH 9, 2016
Contact: Daniel Seaton
Phone: 202-470-5207
Email: [email protected]

Washington, D.C. (March 9, 2016) –Biotechnology Innovation Organization (BIO) Executive Vice President for Health Policy Dan Durham released the following statement regarding yesterday's proposed Part B Drug Payment Model and ASPE Issue Briefs:

"BIO is thoroughly reviewing the Medicare Part B Drug Payment Model released yesterday, and we intend to submit comments reflecting our comprehensive feedback on the proposal. However, upon initial review we are gravely concerned that the Model threatens to disrupt the successful reimbursement framework for drugs covered under the Medicare Part B program, particularly for rural and smaller provider groups. We are also disappointed that CMS developed this proposed model with little, if any, stakeholder input, despite its broad impact on a vital government program.

"The patients served under Part B include those fighting cancer, multiple sclerosis, and rheumatoid arthritis—those most in need of the medicines their doctors prescribe. Reducing provider reimbursement for these patients' therapies can disrupt patient access, diminish their health outcomes, and increase overall healthcare expenditures—which can offset any short-term savings. Moreover, evidence shows that the ASP framework is working. A 2011 study found that "proposals to alter Medicare Part B drug reimbursement place a successful program and the patients it supports at risk, and thus, are neither sound nor sustainable reform policies that support overall debt reduction." The same study also found that the current reimbursement formula "constrain[s] costs in an efficient market-driven manner that allows both small providers in rural areas and large practices to provide ongoing care to Medicare beneficiaries."

"Further, cutting reimbursement to community providers risks accelerating the shift of patients into more expensive care settings, which studies have found drives up overall costs.

"Any approach to refining the program should focus on improving patient access, the quality of care they receive, and their long-term outcomes, not just on the short-term cost of care alone. Any such approach also should include a study of the impact on patients and providers, while also taking into account the cuts already imposed through sequestration. Moreover, while value-based reimbursement arrangements can be one promising mechanism to recognize the value of innovative therapies, they must be considered thoughtfully and must eschew a limited range of approaches to avoid stalling innovation in the long term. BIO will continue to explore policies that achieve these goals, but the Part B Drug Model released yesterday fails to meet these basic criteria.

"We are also concerned that the ASPE Issue Briefs released this afternoon, purportedly to justify the need for the Model, fail to accurately represent the overall marketplace and value proposition of prescription drugs. They do this by cherry-picking data from years with unusually high prescription drug expenditure increases. Historically, expenditures on prescription drugs have been quite stable as a percentage of overall health spending, even if rates of growth vary cyclically as new, high-value therapies become approved and older therapies face generic competition. Further, these reports fail to accurately and fully account for the savings which medicines produce in other areas of healthcare spending by reducing the need for services such as hospital stays or physician visits.

"We urge the Agency to consider input from all affected stakeholders in deciding whether to proceed with this demonstration."

Upcoming BIO Events

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.